Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion‐Dependent β‐Thalassemia
Authors:
Open Access
- 7 June 2026
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 101 (8) , 1969-1979
Abstract
Exagamglogene autotemcel (exa‐cel) is a one‐time, ex vivo, CRISPR‐Cas9 gene edited cell therapy approved for patients with transfusion dependent β‐thalassemia (TDT) aged 12–35 years. In a Phase 3 study (CLIMB THAL‐111), exa‐cel treatment resulted in reactivation of fetal hemoglobin and increases in total hemoglobin, leading to transfusion independence in 91% of participants. Here, we report on the impact of exa‐cel treatment on measures of ineffective erythropoiesis and iron homeostasis, which were secondary and exploratory endpoints in CLIMB THAL‐111 and the CLIMB‐131 long‐term follow‐up study. Prior to exa‐cel infusion, all participants were receiving regular red blood cell transfusions and iron chelation therapy. At time of data cut (April 2025), 98% of participants (55 of 56) had been transfusion independent for ≥ 12 months and 38 (68%) had discontinued iron removal therapy (mean duration off iron removal therapy 19.4 months). Following transfusion independence and cessation of iron removal therapy, erythroferrone concentrations decreased and hepcidin levels normalized in all participants, indicating correction of ineffective erythropoiesis and restoration of iron homeostasis. Further supporting this finding, improvements and trends toward normalization were seen in key erythropoiesis biomarkers, including erythropoietin levels, reticulocyte counts, and soluble transferrin receptor concentrations. Iron overload biomarkers, including ferritin, liver iron concentration, and cardiac T2*, decreased and then remained stable throughout follow‐up, even after cessation of iron removal therapy. These results demonstrate restoration of effective erythropoiesis and iron homeostasis after exa‐cel infusion in the setting of transfusion independence following reactivation of fetal hemoglobin. (CLIMB THAL‐111 and CLIMB‐131; Clinical Trials.gov numbers NCT03655678 and NCT04208529).Keywords
Funding Information
- Vertex Pharmaceuticals
This publication has 31 references indexed in Scilit:
- Iron Overload Following Hematopoietic Stem Cell Transplantation: Prevalence, Severity, and Management in Children and Adolescents with Malignant and Nonmalignant DiseasesTransplantation and Cellular Therapy, 2023
- Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: It’s more a matter of burden or more of exposure to toxic iron form?Leukemia Research, 2022
- Current status of beta‐thalassemia and its treatment strategiesMolecular Genetics & Genomic Medicine, 2021
- Erythroferrone structure, function, and physiology: Iron homeostasis and beyondJournal of Cellular Physiology, 2020
- Revisiting the non‐transfusion‐dependent (NTDT) vs. transfusion‐dependent (TDT) thalassemia classification 10 years laterAmerican Journal of Hematology, 2020
- Iron overload: Effects on cellular biochemistryClinica Chimica Acta, 2020
- Challenges of blood transfusions in β-thalassemiaBlood Reviews, 2019
- A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?Blood Reviews, 2018
- A Multicenter Retrospective Analysis Stressing the Importance of Long-Term Follow-Up after Hematopoietic Cell Transplantation for β-ThalassemiaTransplantation and Cellular Therapy, 2017
- Hereditary persistence of fetal hemoglobin in two patients with KLF1 haploinsufficiency due to 19p13.2–p13.12/13 deletionAmerican Journal of Hematology, 2016